The Rotation Is Finally Broadening — and It's Paying for It With Health Care

Market regime

The 10/06 tape was modestly positive at the index level but directionally important underneath. The average US stock gained +0.07% on 1,614 advancers to 1,392 decliners — the fourth consecutive session of improving participation — while the share of names holding their 50-day rose again to 28.7% (up from 22.7% on 9/30). Average RSI has climbed from 40.9 to 45.6 over the same stretch. This is a repair, not a breakout: the median name is still down ~4.4% on the month, and outside Technology no sector has more than 44% of members above their 50-day.

The tell is where the money came from. With only 212 stocks up more than 3% against 205 down more than 3%, and 85 up >5% versus 82 down >5%, the market is doing something it has not done all quarter: funding new leadership by liquidating old leadership, rather than by appreciating everything. Utilities rose +2.0% on the day (XLU +3.0% on 2.2x volume) yet are still down 4.7% over the month — a violently squeezed, still-broken sector. Health Care fell -2.2% on the day and -7.8% on the month. Symmetrical-triangle breakouts (11) now outnumber ascending ones (3), and downside breaks still trail upside only modestly at 9 to 15.

Mega forces

1. AI capital spending is re-rating its physical supply chain, not just its chips. Information Technology is the only sector with majority participation (57.5% above the 50-day, +3.9% 1M), but the day's leaders were the picks-and-shovels names: CIEN +13.8%, Marvell +5.8%, MACOM +6.8%, Fabrinet +7.8%, Comfort Systems +6.1%, EMCOR +5.8%, Quanta +5.3%. Semiconductor Capital Equipment is the best theme on the month at +16.1%. Credit markets are confirming rather than fading this.

2. Power is the binding constraint — and it just got repriced violently. Talen +12.4%, Constellation +12.2%, Vistra +10.8%, all on 3-5x volume, versus a Power Generation theme that is still negative on the month. This is the market separating merchant power with data-center offtake from regulated utilities (15.1% above the 50-day, average RSI 47) — a dispersion trade, not a sector trade.

3. A real, cash-funded M&A wave. OPCH surged +32.7% on 20x volume on a $32.05/share cash takeout; RXO +22.5% on a CHRW deal while the acquirer fell 10.8%; PTC +33.5% on the Schneider bid. Bilateral deal announcements are now daily, which is typical of late-cycle confidence and a tailwind for small/mid-cap value with strategic assets.

4. The cost-of-capital trade is inverted. Gold fell -6.0% and silver -7.3% in a month when broad commodities rose +2.5% and oil +2.1%; Gold & Silver Mining is down -11.9% and Rare Earth -15.7%. Real assets that rallied on debasement are being sold to fund industrial and power exposure. Meanwhile the 10Y sits at 4.63%, the 10Y-2Y spread at +0.51%, and long Treasuries (TLT -5.6% 1M) keep losing.

What's working

Technology infrastructure (optical, networking, semis equipment, data-center electrical), merchant power, and industrial electrical/mechanical contractors. What to avoid: pre-revenue biotech — Neurology & Rare Diseases -16.8%, Autoimmune -13.4%, Oncology -10.8%, with TWST -18.6%, TXG -17.5% and TEM -13.8% in a single session; the rate-sensitive complex (Residential Mortgage REITs -14.7%, Real Estate -7.6% 1M, Financials -5.6% 1M); and consumer/auto cyclicals (EV Makers -12.2%, Automotive Repair -14.1%).

Strategy

Stay with the compute-and-electrons complex, but rotate within it toward names whose earnings arrive over the next two to three quarters rather than five years out — the sharp drop in high-multiple clinical biotech shows what happens when duration meets a 4.6% 10-year. Hold small/mid-cap industrial and infrastructure exposure as M&A optionality. Fade rallies in the beaten-down rate-sensitives until the share of stocks above the 50-day clears 40%; the current repair is real but has three more sessions of fuel at best before it needs confirmation from Health Care and Financials.